[go: up one dir, main page]

WO2003007869A3 - Compositions immunogenes contenant des antigenes, des vecteurs geniques et des microspheres biodegradables chargees d'adjuvants - Google Patents

Compositions immunogenes contenant des antigenes, des vecteurs geniques et des microspheres biodegradables chargees d'adjuvants Download PDF

Info

Publication number
WO2003007869A3
WO2003007869A3 PCT/BR2002/000099 BR0200099W WO03007869A3 WO 2003007869 A3 WO2003007869 A3 WO 2003007869A3 BR 0200099 W BR0200099 W BR 0200099W WO 03007869 A3 WO03007869 A3 WO 03007869A3
Authority
WO
WIPO (PCT)
Prior art keywords
adjuvants
gene
codifies
gene vectors
compositions containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/BR2002/000099
Other languages
English (en)
Other versions
WO2003007869A2 (fr
Inventor
Silva Celio Lopes
Jose Maciel Junior Rodrigues
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidade Federal de Minas Gerais
Original Assignee
Universidade Federal de Minas Gerais
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidade Federal de Minas Gerais filed Critical Universidade Federal de Minas Gerais
Priority to CA002453959A priority Critical patent/CA2453959A1/fr
Priority to EP02744957A priority patent/EP1420823A2/fr
Priority to AU2002317056A priority patent/AU2002317056A1/en
Publication of WO2003007869A2 publication Critical patent/WO2003007869A2/fr
Anticipated expiration legal-status Critical
Publication of WO2003007869A3 publication Critical patent/WO2003007869A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des compositions capables de stimuler une réponse immune chez un hôte auquel on a inoculé un antigène d'intérêt ou le vecteur génique qui le codifie. Cette composition comporte des microsphères à base de copolymères dérivés d'acide lactique et d'acide glycolique enrobant des antigènes, des vecteurs géniques et/ou des adjuvants présentant des propriétés immunostimulatrices obtenues à partir de fractions mycobactériennes. L'invention se caractérise en ce que l'on utilise du tréhalose dimycolate associé à une protéine de choc thermique ou au plasmide renfermant le gène le codifiant, enrobé dans des microsphères dont les dimensions n'excèdent pas 10 νm, capable d'induire des anticorps spécifiques et des réponses immunes cellulaires, ainsi que la sécrétion de cytokines impliquées dans la protection contre des maladies infectieuses et cancers, après administration d'une ou de plusieurs doses.
PCT/BR2002/000099 2001-07-17 2002-07-17 Compositions immunogenes contenant des antigenes, des vecteurs geniques et des microspheres biodegradables chargees d'adjuvants Ceased WO2003007869A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002453959A CA2453959A1 (fr) 2001-07-17 2002-07-17 Compositions immunogenes contenant des antigenes, des vecteurs geniques et des microspheres biodegradables chargees d'adjuvants
EP02744957A EP1420823A2 (fr) 2001-07-17 2002-07-17 Compositions immunogenes contenant des antigenes, des vecteurs geniques et des microspheres biodegradables chargees d'adjuvants
AU2002317056A AU2002317056A1 (en) 2001-07-17 2002-07-17 Immunogenic compositions containing antigens, gene vectors and adjuvants-loaded biodegradable microspheres

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
BRPI0103887 2001-07-17
BR0103887-7A BR0103887C1 (pt) 2001-07-17 2001-07-17 Composições imunogênicas contendo microesferas biodegradáveis encapsulando antìgenos, vetores gênicos e adjuvantes
BRC10103887 2002-07-04

Publications (2)

Publication Number Publication Date
WO2003007869A2 WO2003007869A2 (fr) 2003-01-30
WO2003007869A3 true WO2003007869A3 (fr) 2004-03-18

Family

ID=3947962

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2002/000099 Ceased WO2003007869A2 (fr) 2001-07-17 2002-07-17 Compositions immunogenes contenant des antigenes, des vecteurs geniques et des microspheres biodegradables chargees d'adjuvants

Country Status (5)

Country Link
EP (1) EP1420823A2 (fr)
CN (1) CN1549728A (fr)
BR (1) BR0103887C1 (fr)
CA (1) CA2453959A1 (fr)
WO (1) WO2003007869A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007001448A2 (fr) 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Particules polymeres revetues a diffusion regulee comme vecteurs efficaces d'administration par voie orale de produits biopharmaceutiques
CN1317560C (zh) * 2005-10-19 2007-05-23 华中科技大学 一种提高量子点编码微球的编码稳定性的方法
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
CA2648099C (fr) 2006-03-31 2012-05-29 The Brigham And Women's Hospital, Inc Systeme pour l'administration ciblee d'agents therapeutiques
WO2007133807A2 (fr) 2006-05-15 2007-11-22 Massachusetts Institute Of Technology Polymères pour particules fonctionnelles
US9381477B2 (en) 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
WO2008098165A2 (fr) 2007-02-09 2008-08-14 Massachusetts Institute Of Technology Bioréacteur oscillant pour la culture de cellules
JP2010523595A (ja) 2007-04-04 2010-07-15 マサチューセッツ インスティテュート オブ テクノロジー ポリ（アミノ酸）ターゲッティング部分
CN101861165A (zh) 2007-10-12 2010-10-13 麻省理工学院 疫苗纳米技术
CN101376023B (zh) * 2008-10-10 2011-12-28 山西海森生物制品有限公司 一种禽用疫苗缓释剂及其制备与接种方法
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
EP2661253B1 (fr) * 2011-01-04 2017-04-19 Archivel Farma, SL Formulation de liposomes pour le traitement ou la prévention de la tuberculose
WO2013104943A1 (fr) 2012-01-12 2013-07-18 Archivel Farma, S.L. Vaccin mycobacterium tuberculosis-complex (mtb-c) contre l'asthme
WO2014046983A1 (fr) 2012-09-21 2014-03-27 Intensity Therapeutic Procédé de traitement du cancer
EP3142852B1 (fr) 2014-05-14 2021-12-01 Dicar, Inc. Couvercle de protection comportant des renforts à motifs

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01207237A (ja) * 1988-02-15 1989-08-21 Sawai Seiyaku Kk 腫瘍壊死因子誘起剤
US6048551A (en) * 1997-03-27 2000-04-11 Hilfinger; John M. Microsphere encapsulation of gene transfer vectors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01207237A (ja) * 1988-02-15 1989-08-21 Sawai Seiyaku Kk 腫瘍壊死因子誘起剤
US6048551A (en) * 1997-03-27 2000-04-11 Hilfinger; John M. Microsphere encapsulation of gene transfer vectors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 19890821, Derwent World Patents Index; AN 1989-282538 *

Also Published As

Publication number Publication date
EP1420823A2 (fr) 2004-05-26
CA2453959A1 (fr) 2003-01-30
BR0103887A (pt) 2003-08-05
CN1549728A (zh) 2004-11-24
BR0103887C1 (pt) 2005-11-08
WO2003007869A2 (fr) 2003-01-30

Similar Documents

Publication Publication Date Title
WO2003007869A3 (fr) Compositions immunogenes contenant des antigenes, des vecteurs geniques et des microspheres biodegradables chargees d'adjuvants
WO2003011223A3 (fr) Composes immunomodulants et methodes d'utilisation
KR970707281A (ko) 풀리뉴클레오티드 결핵 백신(A polynucleotide tuberculosis vaccine)
IL144671A0 (en) Immunological adjuvants compounds compositions and methods of use thereof
CA2421683A1 (fr) Microparticules de transport d'acides nucleiques heterologues
PT1104306E (pt) Composicoes de cpg e adjuvantes de saponina e seus metodos
Magiri et al. Recent advances in experimental polyphosphazene adjuvants and their mechanisms of action
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
CA2523084A1 (fr) Vaccin contre la tuberculose a efficacite amelioree
CA2391843A1 (fr) Compositions vaccinales contre le vhc
WO2005007673A3 (fr) Peptides immunogenes
Zhu et al. Enhancement of DNA vaccine potency against herpes simplex virus 1 by co-administration of an interleukin-18 expression plasmid as a genetic adjuvant
Rolph et al. CD40 signaling converts a minimally immunogenic antigen into a potent vaccine against the intracellular pathogen Listeria monocytogenes
Peacey et al. Virus-like particles from rabbit hemorrhagic disease virus can induce an anti-tumor response
WO2015138471A1 (fr) Poxvirus inactivé par la chaleur améliorant les résultats de vaccination
AU2001284354A1 (en) Immunological adjuvant compounds, compositions, and methods of use thereof
WO2000006198A3 (fr) Adjuvant comprenant un tensioactif pulmonaire
WO2005012538A3 (fr) Vaccination acceleree
Saavedra et al. CpG‐containing ODN has a limited role in the protection against Toxoplasma gondii
WO2001010469A3 (fr) Sequence
Li et al. The synthetic antimicrobial peptide KLKL5KLK enhances the protection and efficacy of the combined DNA vaccine against Mycobacterium tuberculosis
WO2001015727A3 (fr) Compositions de polymeres et d'adjuvants a base de saponine immunostimulants et leurs utilisations
CA2273922A1 (fr) Nouvelles compositions a base de saponine et leurs utilisations
Lunn Immunological basis of vaccination
WO2002004497A3 (fr) Peptides a antigenes multiples assurant l'immunite contre streptococcus pneumoniae

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2453959

Country of ref document: CA

Ref document number: 87/CHENP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2002744957

Country of ref document: EP

Ref document number: 200401274

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 20028171861

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002744957

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2002744957

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)